Conclusion (from the same paper)
Laboratory testing of the TT vaccine used in the WHO Kenya campaign 2013-2015 showed that some of the vials contained a TT/βhCG conjugate consistent with the WHO’s goal to develop one or more anti-fertility vaccines to reduce the rate of population growth, especially in targeted LDCs such as Kenya. While it is impossible to be certain how the βhCG got into the Kenya vaccine vials testing positive for it, the WHO’s deep history of research on antifertility vaccines con- jugating βhCG with TT (and other pathogens), in our opinion, makes the WHO itself the most plausible source of the βhCG conjugate found in samples of “tetanus” vaccine being used in Kenya in 2014. Moreover, given that all vaccine manufacturers and vaccine testing laboratories must be WHO certified, their responsibility for whatever has happened in the Kenyan immunization program can hardly be overemphasized.